论文部分内容阅读
目的比较重组人门冬胰岛素注射液(IASP)和可溶性人胰岛素(HSI)对2型糖尿病病人餐后血糖的影响。方法2002-102003-05对中日友好医院的42例已接受每日多次人胰岛素治疗的2型糖尿病患者经过2周的导入期治疗后随机分为两组,分别以IASP和HSI治疗4周,比较两组餐后1h、2h血糖的变化。结果经过4周的治疗,IASP组餐后1h血糖下降幅度显著大于HSI组[(2·1±2·0)mmol/L对(0·9±1·9)mmol/L,P<0·05],两组空腹血糖、餐后2h血糖和果糖胺的水平差异无显著性。HSI组治疗期间发生1例低血糖事件,两组均未发生严重低血糖事件和其他严重不良事件。结论与人HSI相比,IASP注射液能更有效地降低餐后1h血糖,安全性和耐受性良好。
Objective To compare the effect of recombinant human insulin aspart (IASP) and soluble human insulin (HSI) on postprandial blood glucose in type 2 diabetic patients. Methods A total of 42 patients with type 2 diabetes mellitus who received daily multiple insulin injections at China-Japan Friendship Hospital were divided into two groups randomly after 2 weeks of induction period and were treated with IASP and HSI for 4 weeks respectively The changes of blood glucose in 1h and 2h after meal were compared between the two groups. Results After 4 weeks’ treatment, the decrease of blood glucose level in IASP group was significantly greater than that in HSI group ([(2.1 ± 2.0) mmol / L vs (0.9 ± 1.9) mmol / L, P <0 · 05], fasting blood glucose, postprandial 2h blood glucose and fructosamine levels were not significantly different. One episode of hypoglycaemia occurred during the HSI treatment and no severe hypoglycaemia or other serious adverse events occurred in either group. Conclusion Compared with human HSI, IASP injection can reduce blood glucose more effectively 1h after meal with good safety and tolerability.